First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3731-3733
10.1182/blood-2022-163160